复杂冠脉病变合并慢性肾脏病患者中的血管内成像指导PCI
该研究为RENOVATE-COMPLEX-PCI多中心随机临床试验的预设亚组分析,纳入2018年5月至2021年5月韩国1639例复杂冠脉病变行PCI患者,比较血管内成像指导与单纯造影指导。CKD组296例,非CKD组1343例。3年靶血管失败在CKD组为13.3% vs 23.3%(HR 0.51,95%CI 0.27-0.93,P=0.03),非CKD组为6.4% vs 9.9%(HR 0.66,95%CI 0.44-0.99,P=0.05)。CKD组获益主要来自心源性死亡或靶血管相关心肌梗死降低(9.4% vs 22.2%,HR 0.39,95%CI 0.20-0.76,P=0.006),非CKD组主要来自靶血管血运重建降低(3.0% vs 5.5%,HR 0.55,95%CI 0.30-0.99,P=0.05)。肾小球滤过率≥30且<60 mL/min/1.73m²者获益最大(8.8% vs 21.2%,HR 0.28,95%CI 0.11-0.68,P=0.02)。
要点
- 复杂冠脉病变PCI中,血管内成像指导较造影指导降低3年TVF:CKD组13.3% vs 23.3%(HR 0.51,95%CI 0.27-0.93,P=0.03)。
- 非CKD组同样获益:TVF 6.4% vs 9.9%(HR 0.66,95%CI 0.44-0.99,P=0.05)。
- CKD组获益主要来自心源性死亡或靶血管相关心肌梗死降低:9.4% vs 22.2%(HR 0.39,95%CI 0.20-0.76,P=0.006)。
- 非CKD组获益主要来自靶血管血运重建降低:3.0% vs 5.5%(HR 0.55,95%CI 0.30-0.99,P=0.05)。
- 肾小球滤过率≥30且<60 mL/min/1.73m²者获益最大:8.8% vs 21.2%(HR 0.28,95%CI 0.11-0.68,P=0.02)。
适用人群与场景
- 复杂冠脉病变并接受PCI的患者,纳入时伴或不伴慢性肾脏病(CKD),来源于韩国多中心随机临床试验RENOVATE-COMPLEX-PCI。
- CKD组296例,平均(SD)年龄70.3(9.4)岁,平均(SD)血清肌酐2.9(5.3)mg/dL;非CKD组1343例,平均(SD)年龄64.5(10.1)岁,平均(SD)血清肌酐0.8(0.2)mg/dL。
研究设计与关键结果
- 研究类型:RENOVATE-COMPLEX-PCI的预设亚组分析,该试验为多中心随机临床试验;2018年5月至2021年5月纳入1639例(男性1300例,79.3%)复杂冠脉病变行PCI患者,分为CKD组(296例)和非CKD组(1343例);数据于2023年1月至6月分析。
- 干预:PCI在血管内成像指导或单纯造影指导下完成。
- 主要终点:3年靶血管失败(TVF),定义为心源性死亡、靶血管相关心肌梗死或临床驱动的靶血管血运重建的复合终点。
- CKD组TVF:血管内成像指导13.3% vs 造影指导23.3%(HR 0.51,95%CI 0.27-0.93,P=0.03)。
- 非CKD组TVF:血管内成像指导6.4% vs 造影指导9.9%(HR 0.66,95%CI 0.44-0.99,P=0.05)。
- CKD组心源性死亡或靶血管相关心肌梗死:血管内成像指导9.4% vs 造影指导22.2%(HR 0.39,95%CI 0.20-0.76,P=0.006)。
- 非CKD组靶血管血运重建:血管内成像指导3.0% vs 造影指导5.5%(HR 0.55,95%CI 0.30-0.99,P=0.05)。
- 肾小球滤过率≥30 mL/min/1.73m²且<60 mL/min/1.73m²者TVF:血管内成像指导8.8% vs 造影指导21.2%(HR 0.28,95%CI 0.11-0.68,P=0.02)。
证据类型、等级与局限
- 证据类型:多中心随机临床试验的预设亚组分析。
- 局限:原文未报告局限性。
对床旁实践的改变
- 对于复杂冠脉病变行PCI的患者,无论是否合并CKD,血管内成像指导较单纯造影指导与更低的3年TVF风险相关;合并CKD者获益主要来自心源性死亡或靶血管相关心肌梗死的降低,非CKD者获益主要来自靶血管血运重建的降低。
- 肾小球滤过率≥30 mL/min/1.73m²且<60 mL/min/1.73m²的3期CKD患者从血管内成像指导的复杂PCI中获益最大。
指南或共识出处
- JAMA Netw Open发表的RENOVATE-COMPLEX-PCI预设亚组分析;临床试验注册号NCT03381872。
提炼说明
- 本条依据论文摘要整理;摘要未涉及「诊断标准与关键阈值」「处置流程与药物剂量」「红旗征与不能漏的情况」,故未列出这些栏目;全文请点「阅读原文」。
英文原文(摘要)· 点击展开
IMPORTANCE: As patients with chronic kidney disease (CKD) are more likely to have complex coronary lesions, intravascular imaging guidance in percutaneous coronary intervention (PCI) for this population could be potentially beneficial.
OBJECTIVES: To investigate whether the outcomes of intravascular imaging-guided procedural optimization would be different according to the presence of CKD.
DESIGN, SETTING, AND PARTICIPANTS: This was a prespecified substudy of RENOVATE-COMPLEX-PCI, a recently published multicenter randomized clinical trial in Korea studying the benefits of intravascular imaging for complex coronary lesions. Patients with complex coronary lesions, with or without CKD, were enrolled between May 2018 and May 2021. Data were analyzed from January to June 2023.
INTERVENTIONS: PCI in each group was done either under the guidance of intravascular imaging or angiography alone.
MAIN OUTCOMES AND MEASURES: The primary end point was target vessel failure (TVF) at the 3-year point, defined as a composite of cardiac death, target vessel-related myocardial infarction, or clinically driven target vessel revascularization.
RESULTS: A total of 1639 patients (1300 male [79.3%]) treated with PCI for complex coronary lesions were stratified into CKD (296 participants) and non-CKD (1343 participants) groups. The mean (SD) age of each group was 70.3 (9.4) and 64.5 (10.1) years, and mean (SD) estimated serum creatinine was 2.9 (5.3) and 0.8 (0.2) mg/dL for CKD and non-CKD groups, respectively. Intravascular imaging-guided revascularization was associated with significantly lower incidence of the primary end point compared with angiography-guided revascularization in both CKD (13.3% vs 23.3%; hazard ratio [HR], 0.51; 95% CI, 0.27-0.93; P = .03) and non-CKD (6.4% vs 9.9%; HR, 0.66; 95% CI, 0.44-0.99; P = .05) groups. The significantly lower incidence of the primary end point was mainly associated with the lower risk of cardiac death or target vessel-related myocardial infarction (9.4% vs 22.2%; HR, 0.39; 95% CI, 0.20-0.76; P = .006) in the CKD group and by target vessel revascularization (3.0% vs 5.5%; HR, 0.55; 95% CI, 0.30-0.99; P = .05) in the non-CKD group. Those with a glomerular filtration rate of at least 30 mL/min/1.73m2 and less than 60 ml/kg/1.73m2 showed the greatest benefit from imaging-guided complex PCI (8.8% vs 21.2%; HR, 0.28; 95% CI, 0.11-0.68; P = .02).
CONCLUSIONS AND RELEVANCE: In this prespecified cohort substudy of the Randomized Controlled Trial of Intravascular Imaging Guidance versus Angiography-Guidance on Clinical Outcomes After Complex Percutaneous Coronary Intervention trial, intravascular imaging guidance showed clinical benefit over angiography guidance in reducing the risk of TVF, regardless of the presence of CKD. The greatest benefits of imaging-guided complex PCI were observed in stage 3 CKD.
TRIAL REGISTRATION: ClinicalTrials.gov Identifier: NCT03381872.
参考来源
- Kwon W, Choi KH, Song YB, et al. Intravascular Imaging in Patients With Complex Coronary Lesions and Chronic Kidney Disease. JAMA Netw Open. 2023. PMID: 38019512. doi:10.1001/jamanetworkopen.2023.45554
供执业医师抢救与诊疗参考,不替代临床判断;剂量请结合体重、肝肾功能和本院药品规格复核,以指南原文为准。